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Abstract: The diastereoselective, trichlorosilane-mediate reduction of imines, bearing different and 
removable chiral auxiliaries, in combination either with achiral bases or catalytic amounts of chiral Lewis 
bases, was investigated to afford immediate precursors of chiral APIs (Active Pharmaceutical Ingredients). 
The carbon-nitrogen double bond reduction was successfully performed in batch and in flow mode, in high 
yields and almost complete stereocontrol. By this metal-free approach, the formal synthesis of rasagiline and 
tamsulosin was successfully accomplished in micro(meso) flow reactors, under continuous flow conditions. 
The results of these explorative studies represent a new, important step towards the development of 
automated processes for the preparation of enantiopure biologically active compounds. 
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1. Introduction 
Rasagiline mesylate (Figure 1), also known as (R)-(+)-N-propargyl-1-aminoindan mesylate, is a commercially 
marketed pharmaceutically active substance, under the brand name azilect®. The racemic form of the drug 
was patented by Aspro Nicholas in the early 1979, and was later found to be indicated for treatment of 
Parkinson’s disease (PD), being effective both as monotherapy in early PD, and as adjunctive in patients with 
advancing PD and motor fluctuations.[1] This chiral amine is a potent second-generation propargylamine 
pharmacophore that selectively and irreversibly inhibits the B-form of the monoamineoxidase enzyme (MAO-
B) over type A by a factor of fourteen.[2] European drug-regulatory authorities approved this potent MAO-B 
inhibitor in February 2005 and the US FDA in May 2006.[3] Although the S-(−)-enantiomer of N-propargyl-1-
aminoindane still exerts some neuroprotective properties, the potency of R-(+)-enantiomer against the MAO-
B enzyme is approximately 1000-fold higher. Different strategies aimed to the preparation of the enantiopure 
compound have been explored,[4] but, at the best of our knowledge, a stereoselective organocatalytic 
approach for the preparation of rasagiline has never been reported so far. We report here a metal-free 
stereoselective strategy for the synthesis of rasagiline and of an advanced intermediate of another API, 
tamsulosin, sold under the trade name flomax as single enantiomer. Active as antagonist for α1a adrenergic 
receptor, It is used to treat symptomatic benign prostatic hyperplasia and to treat urinary retention. Starting 
from this common precursor, different pharmaceutically active compounds could be prepared, having as 
biological targets different receptors such as cholinesterase and monoamine oxidase inhibition [5], σ-
receptors [6] and human adenosine A2A receptor.[7] 
The synthetic plan for the preparation of the two-target molecules involves a metal-free stereoselective 
reduction of imines, easily prepared starting from commercially available ketones (Scheme 1).[8] 
 
Scheme 1. Synthetic strategy for the synthesis of rasagiline and tamsulosin. 
 
2. Results and Discussions 
We initially explored the possibility to use a catalytic amount of chiral Lewis base (LB) for the stereoselective, 
trichlorosilane-mediated reduction of the imine prepared starting from 1-indanone. Two different chiral 
picolinamides, previously developed in our group, were tested.[9-10] Using ephedrine-derived catalyst A, the 
chiral amines were obtained in high yields, both using  PMP (paramethoxyphenyl) and benzyl protected 
imines, but with modest enantioselectivities, up to 60%. e.e. for the (R)-enantiomer. No better results were 
observed with catalyst type B, that is known to lead to the formation preferentially of the (S)-isomer.[10] 
 
 Scheme 2. Enantioselective reductions of imines for the synthesis of rasagiline intermediates. 
 
Then, we decided to explore the use of a chiral auxiliary, by employing α-methylbenzylamine as cheap and 
readily removable element of stereocontrol in the reduction, that was already successfully employed in 
previous works (Scheme 3).[8j] As achiral Lewis base, N,N-dimethyl formamide was selected as well 
established, inexpensive and efficient activator of trichlorosilane for the reduction of ketoimines.[8j-9] 
 
 
Scheme 3. Stereoselective reductions of chiral imines 3c/3d. 
 
Reductions were performed starting from a diastereoisomeric mixture of imine 3, prepared from 1-(R)-
phenylethylamine in a 9:1 (3c:3d) ratio, in favor of the E imine 3c. The best results were achieved working at 
-20°C, and performing the reaction for 36h; the product was obtained in 55% yield and 98:2 diastereomeric 
ratio in favor of the (R,R) stereoisomer 4c (Table 1, entry 5). To achieve complete conversion higher reaction 
temperature were needed (Table 1, entry 6), leading to a small decrease of diastereoselection (90:10 of d.r.).  
 
 
 
Table 1. Reductions of chiral imine 3c/3d. 
Entry LB T (° C) t(h) Conv. (%)a d.r.b 
1 DMF 0 18 67 90:10 
2 DMF -10 18 44 90:10 
3 DMF -10 36 42 90:10 
4c DMF 0 36 77 90:10 
5c DMF -20 36 55 98:2 
6 DMF 0 to rt 18 98 90:10 
7d A -20 36 90 90:10 
8d B -20 36 20 76:24 
9d,e B -20 36 80 >98:2 
c conversions were evaluated on H1-NMR, b d.r. were evaluated on crude mixtures using H1-NMR, c HSiCl3 was 
further added every 12 hours, d reaction was performed using 0.15 eq. of chiral LB, e reaction was promoted 
by the pseudoenantiomer of catalyst B. 
 
Finally, in the attempt to increase further the efficiency of the process, the use of a match combination 
between the chiral auxiliary and the chiral catalyst was investigated. Based on previous works,[9] we selected 
the known favorable combination of catalyst A and 1-(R)-phenylethylamine as chiral auxiliary: the reduction 
was accomplished in 90% conversion and a 90:10 of d.r. ratio (Table 1, entry 7). Since the use of catalyst B, 
that leads to formation of products of (S) configuration,[10]  afforded, as expected, the product in lower 
stereoselectivity (entry 8, mismatch couple with the chiral auxiliary that favours the formation of product 
with (R) configuration), the use of pseudo-enantiomer of catalyst B  allowed to obtain the product 4c in 80% 
conversion and a complete diasteroselectivity (Table 2, entry 9).  
With the best reaction conditions in our hands, we decided to explore the possibility of employing different 
chiral auxiliaries. Since the removal of the α-methylbenzylamine tipycally requires palladium catalysts,[11] 
we focused our attention onto the use of a chiral auxiliary removable without the need of precious transition 
metals. In particular, we selected commercially available (R)-4-methoxy-α-methylbenzylamine and (R)-2-
methyl-2-propanesulfinamide since they could be removed under metal-free conditions.[12], [13]  
Imines 5a and 6a were readily synthesized and their reduction was performed in the presence of 3.5 mol eq. 
of trichlorosilane and stoichiometric amounts of DMF or catalytic amounts of chiral picolinamide A (see 
Scheme 4). 
Imine 5a was efficiently reduced using DMF as achiral LB (Table 2, entry 1), with high conversion (80 %) and 
a complete diasteroselectivity. In order to increase the yield, the reaction was then performed in the 
presence of catalyst A (Table 2, entry 2); complete conversion of the starting material into the chiral amine 
5b and a total stereocontrol of the reaction were observed. 
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Scheme 4. Stereoselective reductions of chiral imines 5a-6a. 
 
Table 2. Reduction of chiral imines 5a-6. 
Entry Imine LB Conv. (%) d.r. 
1a 5a DMF 80 >98:2 
2b 5a A 98 >98:2 
3 a 6a DMF <5 ND 
4c 6a A 99 80:20 
a 5 eq. of DMF were used, b 0.15 eq of catalys were used c the product was obtained as primary amine directly 
after the work up; e.e. was determined by HPLC on chiral column (see the Supporting Information) 
 
Analogously, the reduction of imine 6a was efficiently promoted by catalyst A, affording the product 6b, that 
was in situ deprotected during the basic aqueous work up, to afford the primary chiral amine 1 in quantitative 
yield and 60% e.e. (entry 4, Table 2). 
Considering the raising interesting for the flow preparation of API’s,[14] based on these results and with the 
aim to further accelerate the reaction, we explored the possibility of developing a continuous flow 
methodology for the preparation of rasagiline. Recently our group has demonstrated that HSiCl3-mediated 
diastereoselective imine reduction could be efficiently performed in (micro)-mesoreactors under continuous 
flow conditions.[15]   
The experimental set up involves a coil-reactor, realized by using PTFE tubing (1.58 mm outer diameter, 0.58 
mm inner diameter, 1.89 m length, 500 μL effective volume) coiled in a bundle and immersed in a bath cooled 
to the desired temperature. A syringe pump, equipped with two Hamilton gastight syringes, fed the solution 
containing the imine and the Lewis base dissolved in DCM, and the solution of trichlorosilane in DCM through 
a T-junction into the coil-reactor (Scheme 5). 
 
 
Scheme 5. Continuous flow preparation of an advanced precursor of rasagiline. 
 
Running the reduction of imine 5a at low temperature (17°C), low conversions were detected; when the 
reaction was performed at 30°C, the product was isolated in 83% yield but, as expected, with a lower 
disatereoisomeric ratio (92:8, entry 4, Table 3). In order to achieve a complete stereocontrol, the reaction 
was run in the flow reactor in the presence of catalyst A; operating at 30°C and with a 30 min. residence time, 
the matching combination of an enantiopure catalyst with the chiral auxiliary, the chiral amine 5b was in 
continuo produced in 70% yield as stereoisomerically pure compound (entry 5, Table 3). 
 
Table 3. In-flow synthesis of an advanced intermediate of rasagiline. 
Entry LB Imine T (° C) 
Residence 
time (min.) 
Eq. Conv. (%) d.r. 
1 DMF 5a 17 10 5 20 98:2 
2 DMF 5a 17 20 5 34 98:2 
3 DMF 5a 17 30 5 35 98:2 
4 DMF 5a 30 20 5 83 92:8 
5 A 5a 30 20 0.2 70 >98:2 
 
The synthesis of an advanced intermediate of tamsulosin was then studied. By following the same synthetic 
approach and taking advantage of the previously used chiral auxiliaries, enantiopure imines 7a and 8a were 
synthesized and their reduction studied in batch (Scheme 6). 
 
Scheme 6. In batch synthesis of advanced precursors of tamsulosin.  
 
The results are reported in Table 4; when using an achiral base (DMF), the reduction of imine 7a proceeds 
with a modest diastereoselectivity, and only with catalyst B an improved stereocontrol was obtained, 
although the product was isolated in 50% yield only. However, starting from chiral imine 8a better results 
were achieved; simply using a combination of two very cheap reagents, like trichlorosilane and N,N-
dimethylformamide, the primary amine 2 was directly obtained after the work up in quantitative yield and 
94% e.e. (entry 9, Table 4). 
 
Table 4.  In batch synthesis of tamsulosin precursor 
Entry LB Imine Eq. Conv. (%) d.r. 
1a DMF 7a 5 99 65:35 
2b DMF 7a 5 99 70:30 
3 DMF 7a 5 99 77:23 
4 A 7a 0.15 <5 n.d. 
6 B 7a 0.15 50 92:8 
7 A 8a 0.15 <5 n.d. 
8 B 8a 0.15 45 n.d. 
9c DMF 8a 0.15 99 93:7c  
a reaction performed from 0°C to room temperature, b reaction performed at 0°C, c the product was obtained 
as primary amine directly after the work up; e.e. was determined by HPLC on chiral column (see the 
Supporting Information) 
The reaction was then performed in the previously described flow reactor system (Scheme 7); with imine 7a 
the in-flow reduction nicely reproduced the results of the in batch procedure (entries 1-2, Table 5); 
interestingly, it was possible to achieve the removal of the chiral auxiliary under continuous flow conditions, 
as shown in eq.A of Scheme 5. The continuous hydrogenolysis of chiral amines was performed with a 
ThalesNano H-Cube Mini™, equipped with a 10% Pd/C cartridge; at 50 °C and 50 bar, after 1 hour, chiral 
amine 2 was obtained in quantitative yield. 
H
N
Me
Ph
Me
Flow reactor
(PTFE 500 L)
DCMA
B
HSiCl3 3.5 eq.
H-Cube
Chiral imine 7a .
LB
DCM
NaOH
H2O
T (° C)
NH2
Me
50 °C, 50 bar, 1h
MeOH
MeO
MeO
Flow reactor
(PTFE 500 L)
DCMA
B
HSiCl3 3.5 eq.
Chiral imine 8a .
LB
DCM
NaOH
H2O
T (° C) NH2
Me
MeO
Eq. A
Eq. B
2
2
 
Scheme 7.  In-flow synthesis of chiral amine 2, a tamsulosin precursor. 
 
When enantiopure imine 8a was reduced with DMF and trichlorosilane in the PTFE flow reactor, the chiral 
primary amine 2 was directly produced and was collected out from the flow reactor, after in line basic 
aqueous work up, in 70% isolated yield and 88% e.e. (entries 3-4, Table 5). 
Table 5.  Continuous flow reduction of chiral imines 7a and 8a. 
Entry LB Imine 
Residence 
time (min.) 
Eq. Conv. (%) d.r. 
1 B 7a 20 0.2 60 92:8 
2 B 7a 30 0.2 75 92:8 
3a DMF 8a 20 5 60 94:6a 
4a DMF 8a 30 5 70 94:6a 
a the product was obtained as primary amine directly after the work up; e.e. was determined by NMR with 
chiral shift-agents (see the Supporting Information) 
 3. Conclusions 
In the present study, a stereoselective, metal-free strategy for the synthesis of chiral amines, direct 
precursors of rasagiline and tamsulosin, was developed. After setting up the reaction conditions in batch, the 
stereoselective trichlorosilane-mediated reduction of chiral imines was efficiently performed under 
continuous flow conditions. Chiral primary amines were obtained either by a continuous flow hydrogenolysis, 
or directly out from the flow reactor after an in-line aqueous work up, depending on the chiral auxiliary group 
at the amine nitrogen atom. 
The present work represents a further step towards the development of a multistep continuous flow process 
for the synthesis of enantiomerically pure pharmaceutically relevant amines. 
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